PCI Pharma Services Celebrates Safety Success at Tredegar Site for Sixth Year Running
February 23, 2017 – Manufacturing and Packing –
Philadelphia, USA – February 23, 2017. Pharmaceutical outsourcing supplier PCI Pharma Services has maintained its consistent safety track record, having operated without a single reportable accident at its manufacturing facility in Tredegar, South Wales for the last six years.
The milestone is a significant industry achievement for PCI: it equates to over three million working hours delivered by an average of 300 staff during this six year period. The site provides the global healthcare industry with fully integrated development and manufacturing services, ranging from early phase formulation and analytical development through to commercial manufacture, packaging and commercialization of new products.
PCIís Tredegar site reached this six-year landmark while delivering high quality general services day-to-day, but also with substantial expansion and investment programs within this period. Investments included the building of a contained manufacturing facility for the processing of highly potent molecules, new technologies such as roller compaction for products sensitive to heat and moisture, and Xcelodose technology providing drug in capsule/vial for early stage development and First-in-Man studies. In addition to this, the site acquired a further 26,500 square feet of additional footprint in July 2016 to accommodate the continued expansion of its operations as an integrated service provider for its customers. This latest addition will facilitate the expansion of a number of key departments supporting continued business growth, including analytical and formulation development services.
Commenting on the safety track record, Norman Barras, Managing Director of PCIís Tredegar site, said: ‘Remaining consistently accident-free at this site while undertaking significant construction programs and maintaining first-class operational delivery is a success that all of our employees deserve to be proud of. A record can only be reached through a site-wide appreciation and understanding of the importance of safety. All staff at our Tredegar facility played a vital role in the delivery of this significant safety record which we have now demonstrated for six years. It is their personal commitment to working in a safe and secure environment whilst managing the investment and expansion programs that has led to this outstanding achievement.’
Bill Mitchell, PCI President and CEO, added: ‘Ensuring our customerís products are developed and manufactured in the safest environment possible is intrinsic to the PCI business – for the benefit of our customers and staff alike. We have to provide our clients with absolute reassurance that products are processed safely and securely, whilst delivering on our duty of care responsibilities and ensuring the safety of all our employees. We have reached this safety milestone every year for six years; an accomplishment of this nature is a huge success for our business.’
About PCI Pharma Services
The global healthcare industry trusts PCI for the drug development solutions that increase their productsí speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle ó from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patientsí lives. For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.
Contact
Chantel Richman / Fotini Efstathiou at Remarkable Content
chantel.richman@remarkablegroup.co.uk / fotini@remarkablegroup.co.uk
T: (0) 117 247 0158 | 01962 893 929
